SCHEMBL3235233

SCHEMBL3235233

NC(=O)OCCc1ccc(N)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.57
RAB9A P51151 3/20 0.57
LMNA P02545 3/20 0.55
GFER P55789 1/20 0.50
MET P08581 3/20 0.46
CYP3A4 P08684 3/20 0.45
TSHR P16473 2/20 0.45
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
GLA P06280 1/20 0.45
HPGD P15428 1/20 0.45
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAOB P27338 3/20 0.43
MAOA P21397 3/20 0.43
CYP19A1 P11511 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245538 0.89 LMNA (0.71) NPC1RAB9ALMNAGFERCYP3A4
SCHEMBL1936079 0.84 LMNA (0.55) NPC1RAB9ALMNAMETCYP3A4
SCHEMBL8758151 0.84 MET (0.56) NPC1RAB9ALMNAMETALDH1A1
SCHEMBL5703716 0.82 LMNA (0.53) NPC1RAB9ALMNACYP3A4TSHR
SCHEMBL16244405 0.82 LMNA (0.53) NPC1RAB9ALMNAALDH1A1MAPK1
SCHEMBL16244411 0.82 LMNA (0.53) NPC1RAB9ALMNACYP3A4TSHR
SCHEMBL15650450 0.82 LMNA (0.53) LMNAALDH1A1L3MBTL1MAOBCYP1A2
SCHEMBL6552773 0.82 LMNA (0.53) NPC1RAB9ALMNAMETCYP3A4
SCHEMBL30694096 0.82 NPC1 (0.56) NPC1RAB9AGFERMETCYP3A4
SCHEMBL2540602 0.82 NPC1 (0.56) NPC1RAB9ALMNAGFERMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117838875-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2024-04-09 CN disclosed
CN-117586234-A CDKL 3-targeted small molecule inhibitor HZ1 and derivative HZ1-X thereof 盛韧 2024-02-23 CN disclosed
CN-115867319-B Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2024-01-02 CN disclosed
CN-113347883-B Pesticidal compositions and methods 科迪华农业科技有限责任公司 2023-11-03 CN disclosed
CN-116940562-A Acetamido-phenylbenzamide derivatives and methods of use thereof 希华医药有限公司 2023-10-24 CN disclosed
US-20230256106-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) 2023-08-17 US disclosed
EP-4181963-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF Coval Biopharma (Shanghai) Co., Ltd. (CN) 2023-05-24 EP disclosed
CN-115867319-A Drug delivery system for local delivery of therapeutic agents and uses thereof 上海椿安生物医药科技有限公司 2023-03-28 CN disclosed
CN-115232030-A Aryl urea compound and preparation method and pharmaceutical application thereof 中国医学科学院药物研究所 2022-10-25 CN disclosed
CN-115044383-A Liquid crystal aligning agent, liquid crystal alignment film, and liquid crystal element JSR株式会社 2022-09-13 CN disclosed
US-9249308-B2 Compound having bisazo dye skeleton, pigment composition containing the same, pigment dispersion, ink, and color filter resist composition CANON KABUSHIKI KAISHA (JP) 2016-02-02 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20150259340-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-17 US disclosed
US-20140326931-A1 NOVEL COMPOUND HAVING BISAZO DYE SKELETON, PIGMENT COMPOSITION CONTAINING THE SAME, PIGMENT DISPERSION, INK, AND COLOR FILTER RESIST COMPOSITION CANON KABUSHIKI KAISHA (JP) 2014-11-06 US disclosed
WO-2014060113-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
WO-2010020556-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC NEUROSCIENCES GMBH (DE) 2010-02-25 WO disclosed
US-6727269-B1 ACROMEGALY, PITUITARY ADENOMA OR ENDOCRINE GASTROENTEROPANCEATIC TUMORS INCLUDING THE CARCINOID SYNDROME, AND GASTROINTESTINAL BLEEDING SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-04-27 US disclosed
EP-1140855-A1 TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2001-10-10 EP disclosed
WO-2000040565-A1 TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2000-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230256106-A1 DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF TIE1, TEK, KDR NPC1 90/4885RAB9A 1413/4885LMNA 2725/4885
US-20150259340-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK NPC1 4398/4885RAB9A 872/4885LMNA 3015/4885
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK NPC1 4727/4885RAB9A 944/4885LMNA 3243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.